

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Haymarket Financial LLP, as Security Agent		06/12/2012	LIMITED LIABILITY PARTNERSHIP: UNITED KINGDOM
RECEIVING PARTY DATA			
Name:	EUSA Pharma (USA), Inc.		
Street Address:	One Summit Square, 1717 Langhorne Newton Road, Suite 201		
City:	Langhorne		
State/Country:	PENNSYLVANIA		
Postal Code:	19047		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	0712776	CYTOGEN	
Registration Number:	1847218	CYTOGEN	
Registration Number:	1516999	ONCO-RAD	
Registration Number:	1472854	AEOLUS	
Registration Number:	2897509	QUADRAMET	
Registration Number:	2487745	CAPHOSOL	
Registration Number:	3687447	PROSTASCINT	
CORRESPONDENCE DATA			
Fax Number:	4156932222		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4156932440		
Email:	crhem@cooley.com		
Correspondent Name:	Cooley LLP		

Address Line 1: 101 California Street, 5th Floor
Address Line 4: San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	317094-106 JAZZ
NAME OF SUBMITTER:	C Rhem
Signature:	/CR/
Date:	06/13/2012

Total Attachments: 5
source=US - Release of Trademarks#page1.tif
source=US - Release of Trademarks#page2.tif
source=US - Release of Trademarks#page3.tif
source=US - Release of Trademarks#page4.tif
source=US - Release of Trademarks#page5.tif

**RELEASE OF SECURITY INTEREST
IN TRADEMARK COLLATERAL**

This RELEASE OF SECURITY INTEREST IN TRADEMARK COLLATERAL (this "Release") is made as of June 12, 2012, by Haymarket Financial LLP in its capacity as security agent and trustee for the Secured Parties (in such capacity, the "Security Agent"), in favor of EUSA Pharma, Inc., EUSA Pharma (Holdings), Inc. and EUSA Pharma (USA), Inc. (collectively, the "Grantors"). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Trademark Security Agreement (as defined below), or if not defined therein, in the Pledge and Security Agreement (as defined below).

WITNESSETH:

WHEREAS, Grantors are a party to that certain Pledge and Security Agreement, dated as of April 20, 2011, by and among the Grantors and the other grantors party thereto and the Security Agent (the "Pledge and Security Agreement") pursuant to which the Grantors executed and delivered that certain Trademark Security Agreement, dated as of April 20, 2011 (the "Trademark Security Agreement");

WHEREAS, pursuant to the Trademark Security Agreement, each of the Grantors granted to the Security Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on all of such Grantor's right, title and interest in, to and under the following, whether then owned or existing, or thereafter acquired, developed, created or arising and wherever located: all United States, and foreign trademarks, trade names, trade dress, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, whether or not registered, and with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications listed on Schedule A, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages, and proceeds of suit then or thereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively, the "Trademark Collateral");

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office at Reel 004532, Frame 0658 on May 2, 2011; and

WHEREAS, the Security Agent acknowledges full performance of the Secured Obligations and accordingly has agreed to release the grant of its security interest in and continuing lien on all of the Grantors' right, title, and interest in, to and under the Trademark Collateral, and to reconvey any and all rights in the Trademark Collateral to the Grantors;

NOW THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Security Agent hereby releases, relinquishes and discharges, with respect to each Grantor, all of its security interest in and continuing lien on all such Grantor's right, title, and interest in, to and under the Trademark Collateral, and re-assigns to such Grantor any and all right, title or interest it may have in such Trademark Collateral, all without warranty or representation of any kind.

The Security Agent hereby authorizes the Grantors, or the Grantors' authorized representatives to: (a) record this Release with the United States Patent and Trademark Office and/or any other applicable governmental office or Agency, and (b) file UCC financing statement amendments with the applicable filing office in order to memorialize the release of the lien on and security interest of the Security Agent in the Trademark Collateral.


[Signature page follows]

IN WITNESS WHEREOF, the Security Agent has caused this Release to be duly executed by its duly authorized representatives as of the day and year first above written.

Haymarket Financial LLP
as Security Agent

By:

Name:



S. Beckler

Title:

Principal

SCHEDULE A

TRADEMARK REGISTRATIONS AND APPLICATIONS

Grantor	Registered Owner	Jurisdiction	Trademark	Registration Number/(Serial Number)	Registration Date/(Filing Date)
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	7E11 and Design	78410504	29 April 2004
EUSA Pharma (USA), Inc.	Cytogen Corporation	Canada	Centre of Reading Excellence	1299503	27 April 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	Mexico	Centre of Reading Excellence	946013	28 July 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	Centre of Reading Excellence	78741660	27 October 2005
EUSA Pharma (USA), Inc.	Cytogen Corporation	Canada	CORE	1299506	27 April 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	Mexico	CORE	943943	24 July 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	Mexico	CORE	971810	12 February 2007
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	CORE	78741661	27 October 2005
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	Cytogen	712776	21 March 1961
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	Cytogen and design	1847218	26 July 1994
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	ONCO-RAD	1516999	20 December 1988
EUSA Pharma (USA), Inc.	Cytogen Corporation	Denmark	Oncoscint	VR199901882	07 June 1999
EUSA Pharma (USA), Inc.	Cytogen Corporation	Israel	Oncoscint	74640	23 May 1993
EUSA Pharma (USA), Inc.	Cytogen Corporation	Switzerland	Oncoscint	378948	30 November 1990
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	Onco-Scint	1472854	26 January 1988
EUSA Pharma (USA), Inc.	Cytogen Corporation	Switzerland	Oncotec	378949	30 November 1990
EUSA Pharma (USA), Inc.	Cytogen Corporation	Israel	Oncotec	74641	01 April 1996
EUSA Pharma (USA), Inc.	Cytogen Corporation	Australia	Prostascint	705096	22 May 1997
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	EU	Prostascint	25346	28 January 1998

EUSA Pharma (USA), Inc.	Cytogen Corporation	Mexico	Prostascint	627923	11 October 1999
EUSA Pharma (USA), Inc.	Cytogen Corporation	South Africa	Prostascint	963856	11 February 1999
EUSA Pharma (USA), Inc.	Cytogen Corporation	Switzerland	Prostascint	437534	15 April 1997
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	United States	Prostascint	2048135	25 March 1997
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	United States	Prostascint	78410517	29 April 2004
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	Canada	Quadramet	1228009	24 August 2004
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	Canada	Quadramet	TMA503233	28 October 1998
EUSA Pharma (USA), Inc.	Cytogen Corporation	Mexico	Quadramet	905618	27 October 2005
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	United States	Quadramet	2897509	26 October 2004
EUSA Pharma (USA), Inc.	Cytogen Corporation	Canada	STAMP	1299504	27 April 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	Mexico	STAMP	938659	16 June 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	Mexico	STAMP	941498	29 June 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	STAMP	78741663	27 October 2005
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	Stromal Targeted Ablation of Multiple Pathways	78741668	27 October 2005
EUSA Pharma (USA), Inc.	Cytogen Corporation	Canada	Targeting the Sites and Stages of Cancer Progression	1299495	27 April 2006
EUSA Pharma (USA), Inc.	Cytogen Corporation	United States	Targeting the Sites and Stages of Cancer Progression	78741688	27 October 2005
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	United States	Caphosol	2487745	11 September 2001
EUSA Pharma (USA), Inc.	EUSA Pharma (USA), Inc.	Canada	Caphosol	1451047	